inVentiv: 'site-centricity' essential to enhance trial conduct

By Melissa Fassbender contact

- Last updated on GMT

SCRS currently has more than 2,800 members across the globe. (Image: iStock/daizuoxin)
SCRS currently has more than 2,800 members across the globe. (Image: iStock/daizuoxin)

Related tags: Clinical trial, Vice president

As part of the company’s “site-centric” approach, inVentiv has expanded its relationship with the Society of Clinical Research Sites (SCRS) to elevate the “voice” of clinical sites.

SCRS​ announced that inVentiv has become a Site Engagement Partner, and as such will continue to participate on the SCRS Global Impact Board, which works with the association’s leadership council to provide advice on strategic initiatives for SCRS.

Additionally, inVentiv will host two Site Advocacy Groups (SAGs) in order to gain insights from other SCRS members.

"inVentiv’s expanded partnership with SCRS indicates an awareness of the essential role of sites in clinical research operations​,” Christine Pierre, President, SCRS, told Outsourcing-Pharma.com.

Site Advocacy Groups (SAGs) bring the site voice directly into process development and highlight obstacles that could have held up essential advances​," she added.

Susan Stansfield, PhD, Executive Vice President, Site Centricity Unit, Clinical Division, inVentiv Health, told us the company believes “elevating the ‘voice’ of clinical sites holds tremendous potential for improving clinical trial execution​.”

The company calls this approach “site-centricity,​” which Stansfield says is essential for enhancing trial conduct in an important stage – “during the study start-up period culminating with site activation​.”

As part of this approach the company works with sites to develop solutions to challenges in order to improve delivery of medicines to the market.

Through its position on the SCRS Global Impact Board, inVentiv Health is currently working with SCRS to provide counsel on Site Performance Dashboard and Site Payment approaches. 

Working side-by-side with SCRS membership of dedicated SAGs, we’ll be tackling areas where we believe we can jointly add-value to improving site performance and satisfaction in clinical research​,” said Stansfield.

We believe that through these forums we can uncover actionable insights that will translate into long-term improvements for inVentiv clients and the industry.​”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars